Arda Karaduman: "Genetic testing is the process of analyzing a person's genetic material (DNA) to identify variations or mutations that may be associated with a particular genetic condition or disease. This can be done in order to diagnose a condition, predict the risk of developing a condition, or to determine the likelihood of passing a condition on to offspring. Next-Generation Sequencing is a method of DNA sequencing that allows for the rapid and high-throughput sequencing of large quantities of genetic material. NGS technology has revolutionized the field of genetics and genomics by enabling the simultaneous sequencing of millions or billions of DNA fragments in parallel, reducing the time and cost of sequencing a genome. Data interpretation in Next-Generation Sequencing (NGS) refers to the process of analyzing and making sense of the large amounts of data generated by NGS experiments. GeneXFY is a cloud-based platform for all sub-segments of data interpretation in Next Generation Sequencing and currently in the last phase of its development."
GeneXFY: A cloud-based platform for Next-Generation (DNA) sequencing
Arda Karaduman founded GeneXFY GmbH in Mannheim in December 2022, more precisely in CUBEX ONE. In the interview, he explains why he decided to come to Germany with his start-up from Istanbul and why Mannheim is exactly the right choice for him.
THERE ARE MANY MARKETS AND COUNTRIES IN THE WORLD WHERE YOU COULD HAVE SETTLED. HOW DID YOU FIND THE RIGHT PLACE FOR YOU?
Arda: "I have been serving in the life sciences field for more than a decade and I had the chance to visit more than 50 countries throughout this time. I believe this experience and connections, market information in several countries helped me a lot to draft a business plan with clear goals and location selection criteria in the beginning of 2022. As developing a data analytics platform particularly in genetics business is a niche and collaborative effort, I had identified 3 countries that can help this new initiative grow and prospect in March 2022. After this I had conducted remote interviews and face to face visits to these locations in order to have a better understanding of the ecosystem that might help us better. After an in-depth analysis of the technology development zones in respective countries, I came to a verdict to have presence in Cubex One , Next Mannheim in Baden-Württemberg."
WHY DID YOU DECIDE TO COME TO MANNHEIM?
Arda: "Rationale behind this decision is mainly the great research infrastructure of the region, access to key opinion leaders in bioinformatics, open attitude for collaboration and furthermore the most important criteria is the continuous support and follow-up of Cubex One team."
WHAT MAKES GERMANY AND ESPECIALLY MANNHEIM THE RIGHT PLACE FOR YOU?
Arda: "I perceive Germany as a country with a great research infrastructure especially in bioinformatics and being here, collaborating with other stakeholders developing seems very appealing. On the other hand Mannheim came up a digital health hub once I started my search and that's why I believe Mannheim has precise plans to grow businesses in niche digital health markets like us that would like to change the world in a positive way."
COULD YOU TELL US ABOUT THE TIME BETWEEN THE FIRST CONTACT WITH NEXT MANNHEIM AND THE MOVE OF GENEXFY TO MANNHEIM?
Arda: "We started our conversation in April 2022 and I took the decision to start GeneXFY in Mannheim in September 2022. However this was already a planned process as I took my time to evaluate all the aspects I could define before selection of a new location. After this I could be able to start GeneXFY in mid December 2022."
WHAT MAKES CUBEX OR MANNHEIM THE PERFECT PLACE FOR YOUR BUSINESS?
Arda: "Cubex people are helping me a lot to make things faster as a lot of things do not move as fast as I think. However, I still could not figure out if this is a startup founder's rush or regular. I believe especially introduction to the other stakeholders, helping me out in every issue that I could face even personal settlement process is of great help from Mannheim and Cubex people. I feel that Cubex and Mannheim share my passion to serve the community by developing new and innovative solutions in digital health and life sciences."